TCTMD -- In patients with ST-segment elevation myocardial infarction (STEMI), sirolimus-eluting stents (SES) show sustained efficacy at reducing target vessel revascularization (TVR) compared with bare-metal stents (BMS) out to 3 years, with no difference in safety endpoints. These results are equivalent whether patients receive the glycoprotein IIb/IIIa inhibitors (GPIs) tirofiban or abciximab.
